PROMETEUS-RISE · Protein and Membrane Technology Consortium
Research and Innovation Staff Exchange (RISE) funds short-term exchanges of personnel between academic, industrial and commercial organisations throughout the world.
We create new collaborations and cement existing ones, fostering a seamless transfer of knowledge from academy to industry and vice versa for the benefit of society at large.
We propose to join key expertise in structural biology and biochemistry with state-of-the art facilities for membrane protein high-throughput target selection and expression. A strategic contribution will be provided by SME in key enabling technologies such as virtual screening, organic synthesis, proprietary detergent platform, cellular and in vivo studies for drug lead identification and characterization.
We will deliver a platform for the development of new leads for key health issues such as the design of new antibiotics or new strategies for theranostics and foster a synergistic approach to novel bioactive compounds development between academic and non-academic institutions and SMEs.
The acquisition of new skills from staff will come from secondments aimed at training on research topics not available at the home institutions and attendance to courses, workshops, seminar and conferences.
Proteins – Prometeus will address the need to provide excellent academic groups in Europe that address protein targets dealing with relevant health and technology global issues (antibiotic design, prostatic cancer, cancer theranostics, nanotechnology, food industry, agricultural pest management and aquaculture) with training in key advanced technologies provided by SME or TC large facilities.
Drugs – Prometeus will deliver a global collaboration providing drug leads, “from gene to molecule”. The multidisciplinary character of this task makes efforts of most institutions insufficient to provide a research programme that excels in every aspect of the process.
This project has received funding from the European Union’s Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie
Grant Agreement No. 823780